tranexamic acid has been researched along with Breast Cancer in 18 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0." | 9.07 | Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 7.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "Tranexamic acid (TA) has antifibrinolytic property and is being extensively used in controlling blood loss." | 5.56 | Role of tranexamic acid in axillary lymph node dissection in breast cancer patients. ( Dhar, A; Kataria, K; Kumar, C; Lohani, KR; Ranjan, P; Srivastava, A, 2020) |
| "A randomized double-blind trial has shown that, in 160 women with breast cancer undergoing lumpectomy or mastectomy with axillary clearance, perioperative and postoperative administration of tranexamic acid 1 g three times daily resulted in a significant reduction in the mean postoperative drainage volume compared with patients given placebo (283 versus 432 ml, P < 0." | 5.07 | Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer. ( Haberthuer, F; Harder, F; Kreuter, U; Laffer, U; Oertli, D, 1994) |
| "Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction." | 3.96 | Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. ( Banuelos, J; Harless, CA; Jacobson, SR; Manrique, OJ; Martinez-Jorge, J; Nguyen, MT; Tran, NV; Weissler, JM, 2020) |
| "Its role in reducing postoperative blood loss in breast surgery remains unclear." | 3.01 | The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis. ( Huynh, MNQ; McRae, MC; McRae, MH; Voineskos, S; Wong, CR, 2023) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that can be used to treat and prevent bleeding." | 1.72 | ( Bosselmann, K; Keck, M; Lohmeyer, JA; Müller-Wittig, S; Wittig, KS, 2022) |
| "Tranexamic acid (TA) has antifibrinolytic property and is being extensively used in controlling blood loss." | 1.56 | Role of tranexamic acid in axillary lymph node dissection in breast cancer patients. ( Dhar, A; Kataria, K; Kumar, C; Lohani, KR; Ranjan, P; Srivastava, A, 2020) |
| "A case of advanced breast cancer with cerebral metastasis and pleurisy is reported in which irradiation and cytostatics had failed to retard progressive growth and spread of the tumour." | 1.26 | Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis. ( Astedt, B; Mattsson, W; Tropé, C, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 11 (61.11) | 2.80 |
| Authors | Studies |
|---|---|
| Keck, M | 1 |
| Bosselmann, K | 1 |
| Müller-Wittig, S | 1 |
| Wittig, KS | 1 |
| Lohmeyer, JA | 1 |
| Calpin, GG | 1 |
| McAnena, PF | 1 |
| Davey, MG | 1 |
| Calpin, P | 1 |
| Kerin, MJ | 1 |
| McInerney, N | 1 |
| Walsh, SR | 1 |
| Lowery, AJ | 1 |
| Liechti, R | 1 |
| van de Wall, BJM | 1 |
| Hug, U | 1 |
| Fritsche, E | 1 |
| Franchi, A | 1 |
| Safran, T | 1 |
| Vorstenbosch, J | 1 |
| Viezel-Mathieu, A | 1 |
| Davison, P | 1 |
| Dionisopoulos, T | 1 |
| Huynh, MNQ | 1 |
| Wong, CR | 1 |
| McRae, MC | 1 |
| Voineskos, S | 1 |
| McRae, MH | 1 |
| Sipos, K | 1 |
| Kämäräinen, S | 1 |
| Kauhanen, S | 1 |
| Lohani, KR | 2 |
| Kumar, C | 2 |
| Kataria, K | 2 |
| Srivastava, A | 2 |
| Ranjan, P | 2 |
| Dhar, A | 2 |
| Ausen, K | 1 |
| Hagen, AI | 1 |
| Østbyhaug, HS | 1 |
| Olafsson, S | 1 |
| Kvalsund, BJ | 1 |
| Spigset, O | 1 |
| Pleym, H | 1 |
| Weissler, JM | 1 |
| Banuelos, J | 1 |
| Jacobson, SR | 1 |
| Manrique, OJ | 1 |
| Nguyen, MT | 1 |
| Harless, CA | 1 |
| Tran, NV | 1 |
| Martinez-Jorge, J | 1 |
| Mishra, S | 1 |
| Handa, G | 1 |
| Knight, H | 1 |
| Banks, J | 1 |
| Muchmore, J | 1 |
| Ives, C | 1 |
| Green, M | 1 |
| Soper, DE | 1 |
| Bonnema, J | 1 |
| van Geel, AN | 1 |
| Wiggers, T | 1 |
| Ligtenstein, DA | 1 |
| Choy, A | 1 |
| McCulloch, PG | 1 |
| Oertli, D | 1 |
| Laffer, U | 1 |
| Haberthuer, F | 1 |
| Kreuter, U | 1 |
| Harder, F | 1 |
| Rutqvist, LE | 1 |
| Bolund, C | 1 |
| Friberg, S | 1 |
| Einhorn, N | 1 |
| Wallgren, A | 1 |
| Astedt, B | 1 |
| Mattsson, W | 1 |
| Tropé, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Topical Administration of Tranexamic Acid on Postoperative Bleeding and Seroma Formation in Patients Undergoing Mastectomy: A Prospective Placebo-controlled Double Blinded Randomized Study[NCT02627560] | Phase 4 | 202 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Randomized Study on the Topical Application of Tranexamic Acid to Wound Bed for Hemostasis in the Setting Granulating Wounds Following Mohs Micrographic Surgery[NCT04541303] | Early Phase 1 | 62 participants (Anticipated) | Interventional | 2020-10-08 | Recruiting | ||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| Effects of Tranexamic Acid for Alloplastic Breast Reconstruction: A Randomized Control Trial[NCT04918589] | Phase 3 | 106 participants (Anticipated) | Interventional | 2022-08-31 | Not yet recruiting | ||
| Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma[NCT00307606] | Phase 4 | 40 participants (Anticipated) | Interventional | 2005-12-31 | Recruiting | ||
| Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial[NCT02615366] | Phase 4 | 800 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
3 reviews available for tranexamic acid and Breast Cancer
| Article | Year |
|---|---|
The role of tranexamic acid in reducing post-operative bleeding and seroma formation in breast surgery: A meta-analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Seroma; T | 2023 |
Tranexamic Acid Use in Breast Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Mastectom | 2023 |
The Effects of Tranexamic Acid in Breast Surgery: A Systematic Review and Meta-Analysis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Hematoma; Humans; Postopera | 2023 |
3 trials available for tranexamic acid and Breast Cancer
| Article | Year |
|---|---|
Topical Tranexamic Acid in Breast Reconstruction: A Double-Blind Randomized Controlled Trial.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Breast Ne | 2023 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Topical moistening of mastectomy wounds with diluted tranexamic acid to reduce bleeding: randomized clinical trial.
Topics: Administration, Topical; Aged; Antifibrinolytic Agents; Breast Neoplasms; Double-Blind Method; Femal | 2020 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Breast Diseases; Breast Neoplasms; Contusions; Double-Blind Me | 1994 |
12 other studies available for tranexamic acid and Breast Cancer
| Article | Year |
|---|---|
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Female; Humans; Male; Mastectomy; M | 2022 |
Topical tranexamic acid reduces postoperative hematomas in reduction mammaplasties.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Breast Neoplasms; Cohort Stu | 2023 |
Role of tranexamic acid in axillary lymph node dissection in breast cancer patients.
Topics: Axilla; Breast Neoplasms; Cohort Studies; Female; Humans; Lymph Node Excision; Mastectomy; Prospecti | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
Topics: Adult; Antifibrinolytic Agents; Breast; Breast Implants; Breast Neoplasms; Dose-Response Relationshi | 2020 |
Role of tranexamic acid in axillary lymph node dissection in breast cancer patients: Does it help in reducing lymphedema?
Topics: Breast Neoplasms; Female; Humans; Lymph Node Excision; Lymphedema; Tranexamic Acid | 2021 |
Role of tranexamic acid in axillary lymph node dissection in breast cancer patients: Does it help in reducing lymphedema?
Topics: Breast Neoplasms; Female; Humans; Lymph Node Excision; Lymphedema; Tranexamic Acid | 2021 |
Examining the use of intraoperative tranexamic acid in oncoplastic breast surgery.
Topics: Antifibrinolytic Agents; Breast Neoplasms; Female; Hematoma; Humans; Mammaplasty; Mastectomy; Retros | 2019 |
The intrauterine device: a good thing revisited.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Antineoplastic Agents, Hormonal; B | 2013 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Breast; Breast Neoplasms; Drainage; Exudates and Transudates; Humans; Tranexamic Acid; Wound Healing | 1994 |
Perioperative and postoperative tranexamic acid reduces the local wound complication rate after surgery for breast cancer.
Topics: Anticoagulants; Breast Neoplasms; Humans; Neoplasm Metastasis; Tranexamic Acid | 1995 |
[Treatment of advanced cancer with Cyclocapron (tranexamic acid)].
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Humans; Melanoma | 1977 |
Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis.
Topics: Anticoagulants; Antifibrinolytic Agents; Antineoplastic Agents; Blood Coagulation; Brain Neoplasms; | 1977 |